EGFRvIII T-Cell TandAbs Are Specific and Highly Potent Drug Candidates for the Treatment of a Variety of Solid Tumors

摘要

To harness the cytotoxic capacity of immune effector cells for the treatment of several types of solid tumors, we developed tetravalent, bifunctional antibodies that recognize EGFRvIII, the deletion variant III of EGFR. Their second functionality binds with high affinity to CD3 on T-cells, thereby directing T-cells to eliminate EGFRvIII+ cancer cells. The expression of EGFRvIII on various solid tumor types, and its absence from healthy tissues, provides an opportunity to develop cytotoxic antibodies that solely target cancer, these would spare normal tissues, and substantially reduce the side effects associated with EGFR therapy.